Heart failure with preserved ejection fraction after the PARAGON-HF trial results: current knowledge and future directions

Abstract

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International License (CC BY-NC-ND 4.0), allowing third parties to download articles and share them with others, provided the original work is properly cited, not changed in any way, distributed under the same license, and used for noncommercial purposes only.

Initiation of treatment with sacubitril/valsartan during outpatient cardiac rehabilitation program in an octogenarian with heart failure

“…According to the available data, a significant decrease in NT-proBNP was observed in this patient [5]. Analyzing the results of the similar PARAGON-HF trial also demonstrated the positive impact of ARNI therapy in patients with preserved ejection fraction and specific clinical profiles (ejection fraction < 57% and female gender) in whom evidence-based heart failure therapy is not available [7].…”

The HF-POL study — the first real-life multicenter study of Polish patients with heart failure and left ventricular ejection fraction >40%: Study rationale and design

“…In Poland, HF is the most common direct cause of death. Numerous international studies showed that HF with LVEF >40% is associated with a serious prognosis [4][5][6]. In contrast to HF with reduced LVEF, treatment aimed at improving prognosis in patients with LVEF >40% has a lower class of recommendation (up to IIa), based largely on weaker evidence and/or expert opinions -in the 2021 ESC (class IIb) and 2022 ACC/ACC/HFSA (class IIa) guidelines [1,7,8].…”

The effect of exercise training and physiotherapy on diastolic function, exercise capacity and quality of life in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis

“…Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of heart failure (HF) patients in the community, and the mortality and morbidity are high [1]. However, the established neurohormonal-based therapies, used for treating heart failure with reduced ejection fraction (HFrEF), have failed to improve exercise intolerance and provide favorable clinical outcomes for HFpEF [2].…”

“…However, the established neurohormonal-based therapies, used for treating heart failure with reduced ejection fraction (HFrEF), have failed to improve exercise intolerance and provide favorable clinical outcomes for HFpEF [2]. The study of Lelonek [1] reported that although angiotensin receptor neprilysin inhibitors (ARNIs) may benefit from treatment with HFpEF, the relevance of ARNI in HFpEF still has not been clarified.…”